Oppenheimer Upgrades Chemomab Therapeutics (NASDAQ:CMMB) to “Outperform”

Oppenheimer upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) from a market perform rating to an outperform rating in a report released on Monday morning, MarketBeat.com reports. Oppenheimer currently has $6.00 target price on the stock.

Chemomab Therapeutics Stock Up 11.7 %

Shares of NASDAQ CMMB opened at $0.81 on Monday. Chemomab Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.89. The business’s 50 day moving average price is $0.75 and its 200 day moving average price is $0.64. The firm has a market cap of $8.95 million, a P/E ratio of -0.38 and a beta of 0.39.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.14. During the same quarter last year, the firm earned ($0.72) EPS. As a group, research analysts expect that Chemomab Therapeutics will post -1.2 earnings per share for the current year.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).